KEVIN GAREY to Cost-Benefit Analysis
This is a "connection" page, showing publications KEVIN GAREY has written about Cost-Benefit Analysis.
Connection Strength
0.643
-
Estimated Clinical and Economic Impact through Use of a Novel Blood Collection Device To Reduce Blood Culture Contamination in the Emergency Department: a Cost-Benefit Analysis. J Clin Microbiol. 2019 01; 57(1).
Score: 0.530
-
High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin. 2007 May; 23(5):1057-65.
Score: 0.059
-
An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. Am J Health Syst Pharm. 2006 Apr 15; 63(8):735-9.
Score: 0.055